IMDX
Insight Molecular Diagnostics Inc.
IMDX
Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
Oncocyte NASDAQ: IMDX executives said they continue to target FDA marketing authorization for the GraftAssureDx kidney-transplant rejection test later this year, while preparing for a commercial launc
NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor